Back to mobile site

More on IMRX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.0 Score)

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Immuneering Corporation (NQ:IMRX)
Delayed: 4.19 +0.07 (1.70%)
Prev. Close $4.12  
Open$4.11 
52 Wk High$0.04 
52 Wk Low$0.00 
Day High$4.30 
Day Low$4.07 
P/E N/A  
EPS$-0.09 
Volume1,547,814 

Friends, Peers and Foes (?): TEVA, LLY, ONCY, ALXO, ERAS (more...)

Jun 11, 2026 05:38 PM Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.
Jun 11, 2026 05:33 PM Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA
Jun 11, 2026 05:30 PM Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J
Jun 11, 2026 05:26 PM Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE
Jun 11, 2026 05:23 PM Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter
Jun 11, 2026 05:16 PM Form 8-K Immuneering Corp For: Jun 11
Jun 11, 2026 07:30 AM Immuneering doses first patient in phase 3 pancreatic cancer trial
Jun 11, 2026 07:30 AM Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Jun 11, 2026 07:30 AM Immuneering doses first patient in phase 3 pancreatic cancer trial
Jun 11, 2026 07:30 AM Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
View All Articles

Entities mentioned with IMRX

View All Entities